ASLAN Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018 - 2016
Net Income	-35.03	-44.22	-51.38	-31.59	-16.97	-47.07	Upgrade
Depreciation & Amortization	-	0.35	0.33	0.28	0.3	0.45	Upgrade
Share-Based Compensation	-	2.7	1.98	2.19	0.35	0.04	Upgrade
Other Operating Activities	35.03	-2.15	13.11	-4.88	1.28	21.07	Upgrade
Operating Cash Flow	-	-43.32	-35.96	-34	-15.05	-25.51	Upgrade
Capital Expenditures	-	-0.01	-0.03	-0.05	-0	0	Upgrade
Change in Investments	-	0.28	0.44	0	0	0	Upgrade
Other Investing Activities	-	-	-	0.02	0	0	Upgrade
Investing Cash Flow	-	0.27	0.41	-0.03	0	0.01	Upgrade
Share Issuance / Repurchase	-	7.68	0	102.6	7.64	14.76	Upgrade
Debt Issued / Paid	-	-12.31	4.72	11.84	-0.24	3.01	Upgrade
Other Financing Activities	-	15.35	-	-4.58	-0.23	1.33	Upgrade
Financing Cash Flow	-	10.72	4.72	109.87	7.17	19.09	Upgrade
Net Cash Flow	-	-35.65	-33.27	75.84	-7.88	-6.71	Upgrade
Free Cash Flow	-	-43.33	-35.99	-34.04	-15.05	-25.51	Upgrade
Free Cash Flow Margin	-	-361.09%	-	-	-	-850.21%	Upgrade
Free Cash Flow Per Share	-	-21.07	-20.64	-20.91	-15.66	-31.41	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).